Wednesday, November 2, 2011

Anti-malarial compound from UC Berkeley

UC Berkeley originally licensed the anti-malarial compound artemisinin to Amyris and the Intitute for One World Health (iOWH), with global access provisions in 2004, after receiving a grant from the Gates foundation. Now, they are planning on producing the drug for combination therapy with the help of sanofi in 2012. This semisynthetic compound should lower the price significantly and stabilize the availability of the drug which is originally derived from a plant grown in China and Vietnam. Original Source here For more info: iOWH press release: Here Artemisinin Case Study (Berkeley TTO): Here A great example of the importance of global access licensing!

No comments:

Post a Comment

Please give us input on our fight 4 equal access.